Strategic Partnerships EnGeneIC has established strategic partnerships with prominent entities like SAM Holdings, Singapore Institute of Advanced Medicine Holdings, and ImmunityBio Inc. These collaborations present potential sales opportunities for introducing EnGeneIC's innovative technology platform to new markets and expanding its reach in the biopharmaceutical sector.
Financial Growth With recent financing of $5 million in a pre-IPO round and total funding of $10 million, EnGeneIC is poised for financial growth and potential investment opportunities. Investors seeking promising biotechnology companies with a focus on cancer therapy may find EnGeneIC an attractive option for collaboration or funding.
Cutting-Edge Technology EnGeneIC's proprietary EDV™ nanocell platform represents cutting-edge technology in targeted drug delivery for cancer treatment. Companies looking to leverage innovative solutions in the biotechnology research space could explore partnerships or licensing agreements with EnGeneIC to benefit from their advanced technology platform.
Market Expansion EnGeneIC's development of a potential nanocellular Covid-19 vaccine indicates a proactive approach to addressing current healthcare challenges. This diversification into vaccine development opens up new market segments and sales opportunities for EnGeneIC, especially in the context of ongoing global health needs.
Industry Recognition Being recognized as the most innovative company in healthcare in 2019 highlights EnGeneIC's leadership in driving advancements in cancer therapy. This industry recognition boosts credibility and visibility, potentially attracting partnerships, collaborations, and sales opportunities with organizations looking for pioneering solutions in biopharmaceutical research.
10
$10M
147$10M$50M
64$10M
268$10M$50M
1.6K$100M$1B
87$10M$50M
11
39$10MEnGeneIC uses 8 technology products and services including Google Analytics, Font Awesome, OWL Carousel, and more. Explore EnGeneIC's tech stack below.
| EnGeneIC Email Formats | Percentage |
| FLast@engeneic.com | 49% |
| FMiddleLast@engeneic.com | 1% |
| First.Last@engeneic.com | 1% |
| FLast@engeneic.com | 49% |
Biotechnology ResearchNew South Wales, Australia11-50 Employees
EngeneIC is a biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of chemotherapeutics and functional nucleic acids in cancer. The EDV™ is a first-in-class Cyto-Immunotherapy platform.
Company Overview
Media & News
Funding & FinancialsEnGeneIC has raised a total of $10M of funding over 1 rounds. .
Funding & FinancialsEnGeneIC has raised a total of $10M of funding over 1 rounds. .
1-888-653-2347 
support@leadiq.com